Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Forager International Shares Fund Steve Johnson | “Nutex Health (NASDAQ:NUTX) was the Fund's largest contributor last year, and is continuing to add to returns, driving 1.1% of performance this year. The company's share price is up another 37%, as the business keeps rolling out new hospital facilities and generating strong cash flows. The share price has been extremely volatile, providing multiple opportunities to buy and sell and it ended the year closer to its highs than lows. While it's not as cheap as it was, there is more evidence that our thesis is playing out, the balance sheet is stronger and near-term cash flows are higher. The weighting is lower than it was last year, but Nutex remains a meaningful investment for the Fund.” | BULL | Q2 2026 Jul 15, 2026 | View Pitch |
Forager International Shares Fund Steve Johnson | “The biggest winner for the quarter was also the largest contributor over the past 12 months: Nutex Health (NASDAQ:NUTX). It has been a wild ride. After rising more than tenfold from the Fund's initial purchase in August 2024, and with a significant portion of the investment taken off the table, the stock more than halved between May and September 2025. The explanation was detailed in the September 2025 quarterly letter: short-seller reports, late lodgement of accounts and the appointment of a new auditor. Throughout that period, cash continued to come in. More recently, the company lodged its accounts and the stock rose 60% over in the last three months of the year. Weighting in the portfolio has been actively managed, with exposure increased at lower prices and reduced at higher ones, allowing the portfolio to benefit from the volatility rather than suffer from it. BSD Analysis: Nutex Health is a roll-up in micro-hospital and specialty healthcare services where execution, not vision, determines survival. The moat is thin—local relationships, licensing, and speed to open facilities—rather than defensible scale. Reimbursement complexity and payer mix dominate economics more than patient volumes. Growth via acquisitions magnifies integration risk and balance-sheet strain. Cash flow quality matters because capex and working capital swing quickly. Regulatory scrutiny is constant and unforgiving if compliance slips. The bull case is disciplined expansion with stabilized margins at mature sites. The bear case is dilution and operational noise overwhelming reported growth. Nutex is an execution test masquerading as a growth story.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Forager Australian Shares Fund Steve Johnson | “Nutex Health has executed a dramatic business turnaround following success in binding federal arbitrations against health insurers under the No Surprises Act. High arbitration win rates have driven significant revenue and margin expansion, positioning the company for substantial cash flow generation.” | BULL | Q1 2025 Mar 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
